Affiliation:
1. School of Pharmacy Fudan University Shanghai China
2. Department of Urology Huashan Hospital, Fudan University Shanghai China
Abstract
AbstractSunitinib is the first‐line drug for renal cell carcinoma (RCC) treatment. However, patients who received sunitinib treatment will ultimately develop drug resistance after 6–15 months, creating a huge obstacle to the current treatment of renal cell carcinoma. Therefore, it is urgent to clarify the mechanisms of sunitinib resistance and develop new strategies to overcome it. In this review, the mechanisms of sunitinib resistance in renal cell carcinoma have been summarized based on five topics: activation of bypass or alternative pathway, inadequate drug accumulation, tumour microenvironment, metabolic reprogramming and epigenetic regulation. Furthermore, present and potential biomarkers, as well as potential treatment strategies for overcoming sunitinib resistance in renal cell carcinoma, are also covered.
Funder
National Natural Science Foundation of China
Reference154 articles.
1. From Resistance to Sensitivity: Insights and Implications of Biphasic Modulation of Autophagy by Sunitinib
2. PPARα mediates sunitinib resistance via NF‐κB activation in clear cell renal cell carcinoma;Aimudula A.;International Journal of Clinical and Experimental Pathology,2018
3. THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors
4. THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Nuclear hormone receptors
5. The Concise Guide to PHARMACOLOGY 2021/22: Catalytic receptors;Alexander S. P.;British Journal of Pharmacology,2021